Overview

Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer

Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether our drug, 124I-huA33, can safely detect colorectal cancer.
Phase:
N/A
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
Ludwig Institute for Cancer Research
Treatments:
Antibodies
Immunoglobulins
Iodine